Navigation Links
Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
Date:12/6/2010

NEW YORK, Dec. 6, 2010 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced data presented for the first time at the 52nd Annual Meeting of the American Society of Hematology showing promising clinical activity, safety and tolerability of perifosine in patients with advanced chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma (HL).  KRX-0401 (perifosine) is the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. Key highlights from the two Phase 2 poster presentations are as follows:

Abstract # 2861: "Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib In Heavily Pretreated Patients with Relapsed/Refractory Lymphomas: Preliminary Results of a Phase II Trial"  Study Background:  In this Phase 2 study, 26 patients were enrolled with advanced lymphoma (6 NHL, 4 CLL, 1 Waldenstroms and 15 Hodgkin's lymphoma).  73% of patients were previously refractory to their prior therapy, with 85% of patients having had 4 or more prior therapies.  Perifosine (50 mg BID) was started as a single agent for 28 days; After 28 days, patients achieving partial response (PR) or better were continued on single agent perifosine.  Patients achieving less than a PR were given the combination of perifosine (50 mg BID) plus sorafenib (Nexavar®) at 400 mg BID.

Results:  All of the 4 CLL patients in the study achieved a partial response on single-agent perifosine within one month of treatment and remained on perifosine single agent.  Response durations for each of the 4 patients were 4, 8, 9+ and 12 months.  The remaining 22 patients were administered the combination with sorafenib, where 5 of the 15 (33%) Hodgkin's lymphoma patients ac
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
2. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
3. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
4. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
5. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
6. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
7. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
8. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
9. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... TORONTO , May 22, 2013 /PRNewswire/ ... announced three presentations demonstrating the superiority of the AE37 ... Antigen Express, Inc. ( www.antigenexpress.com ). The presentations will ... Society of Clinical Oncology (ASCO) to be held in ... June 4, 2013. The presentation entitled " ...
(Date:5/22/2013)... , 22. Mai 2013  Grifols, ein ... Barcelona , Spanien, präsentierte ... eine höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) ... Alpha1-Antitrypsinmangel (AAT) auf ein Niveau anhebt, das ... Bereichs liegt. ATT-Mangel ist eine lebensbedrohliche, genetische ...
(Date:5/22/2013)... , May 22, 2013  Medifocus, Inc. (OTCQX: MDFZF and ... , Chief Operating Officer, will present at the Second Annual ... New York City at the Grand ... to begin at 4:00 p.m. EDT and will be available ...   http://wsw.com/webcast/marcum/mfs.v/   For more information and registration, ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3
... 48-week investigational regimen yielded nearly double SVR rate ... protease inhibitor SCH 900518 presented at EASL annual ... SGP ) today reported that final ... its investigational oral hepatitis C protease inhibitor, in ...
... Potential of Fully Human Anti-PS Antibodies and ... Equivalent to the Human Antibody Inhibited Tumor ... More than 90%-DENVER and TUSTIN, Calif., April ... PPHM), a clinical stage biopharmaceutical company ...
Cached Medicine Technology:Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 2Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 3Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model 4
(Date:5/22/2013)... (PRWEB) May 22, 2013 According to a ... “Women Have More Options for Breast Cancer Surgery,” modern medical ... opportunity to approach this disease in a whole new light. ... developed, women now face breast cancer and mastectomies ... goo.gl/ARqoN). , “Before the introduction of plastic surgery to oncology, ...
(Date:5/22/2013)... genomic health disparities from the University of Miami Miller ... Medicine have teamed up to hold the second annual ... in Genomic Medicine." The theme of this year,s ... government to reduce these disparities. , Despite steady improvement ... within underserved groups continue to be more vulnerable to ...
(Date:5/22/2013)... 22, 2013 Award Presented at the ... press release here: http://bit.ly/13DkFfk , Merrill Corporation ... “Information Management Product/Service of the Year” at the 7th ... The Colony Hotel in Palm Beach, Florida. , ... room (VDR) solution that optimizes the due diligence ...
(Date:5/22/2013)... May 22, 2013 Registered Dietitian and Founder ... today on Tatalou.com sharing a recipe for making energy bars ... Healthy Energy Bars ,” takes a recipe modified from one ... twists. , “Every day it gets more and more difficult ... said Chevreau. “The size of the nutrition label continues to ...
(Date:5/22/2013)... 2013 Pamela Isom, President and CEO ... Business Journal’s 2013 Women of Influence Award in recognition ... , The reception took place on Thursday, May 2 ... Influence is particularly humbling for the 5,000 people ICE ... success is to recognize the four to nine lives ...
Breaking Medicine News(10 mins):Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 2Health News:Merrill DataSite New Press Release: Merrill DataSite® Virtual Data Room Honored as “Information Management Product/Service of the Year” 3Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:Pamela Isom, President and CEO of ICE Safety Solutions Inc. Receives 2013 Women of Influence Recognition and Award 2
... (HealthDay News) -- Teens undergoing treatment for alcohol or ... by groups such as Alcoholics Anonymous (AA) and Narcotics ... widely available, little research has looked at how effective ... 127 teen substance abuse-treatment outpatients (95 males, 32 females, ...
... April 16 (HealthDay News) -- Surgery for non-melanoma skin cancer ... mainly due to the increased use of a specific surgical ... in the outer layer of the skin or in skin ... according to the U.S. National Cancer Institute. More than ...
... Reinberg HealthDay Reporter , MONDAY, April 16 (HealthDay ... in the brains of people with multiple sclerosis (MS), researchers ... ONO-4641, "actually caused a reduction in relapses, which is somewhat ... said lead researcher Dr. Timothy Vollmer, a professor of neurology ...
... HealthDay Reporter , MONDAY, April 16 (HealthDay News) -- In a ... participated in the "choking game," in which blood and oxygen to ... produce a euphoric "high." What,s more, the researchers found that ... and many practiced other risky behaviors. "If kids do participate, ...
... Early symptoms of major mental illness can be ... be missed, or even ignored due to conventional wisdom ... deterioration and prolonged patterns of abnormality before diagnosing and ... waiting until someone is so ill that the psychological ...
... thought to play a crucial role in regulating cell proliferation. ... and interact with one another in intact animals., This study ... functional placenta and for balancing the effect of an E2F ... genes in a family of regulatory genes are vital for ...
Cached Medicine News:Health News:12-Step Meetings May Help Teens Beat Alcohol, Drug Abuse 2Health News:Surgery Rates Rising for Non-Melanoma Skin Cancer: Study 2Health News:Experimental Pill for Multiple Sclerosis Shows Promise 2Health News:Experimental Pill for Multiple Sclerosis Shows Promise 3Health News:Young Risk-Takers Drawn to Dangerous 'Choking Game' 2Health News:Young Risk-Takers Drawn to Dangerous 'Choking Game' 3Health News:First contact: Early intervention key in diagnosis and treatment of serious mental illness 2Health News:2 repressor genes identified as essential for placental development 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: